- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01380951
Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB)
June 23, 2011 updated by: The Fifth People's Hospital of Suzhou
Clinical Study of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B
Antiviral treatment on Chronic Hepatitis B (CHB) patients with liver cirrhosis is compulsory and effective.
Telbivudine, which is superior to lamivudine in the treatment of CHB,is considered to be appropriate for the antiviral treatment on CHB patients with liver cirrhosis.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Antiviral therapy on CHB patients with liver cirrhosis is compulsory and effective.
Diseases development can be prevented or delayed if the virus is depressed successfully.
Lamivudine is often used and usually has good efficacy.
However, lamivudine resistance and virus mutation happens a lot.
Telbivudine, which is superior to lamivudine in the treatment of CHB,is considered to be appropriate for the antiviral treatment on CHB patients with liver cirrhosis.
Study Type
Interventional
Enrollment (Anticipated)
120
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Jiangsu
-
Suzhou, Jiangsu, China
- Recruiting
- The Fifth People's Hospital of Suzhou
-
Contact:
- Honghao Zhang, B.A.
- Email: zhanghonghao@medmail.com.cn
-
Principal Investigator:
- Chuanwu Zhu, Doctor
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- liver cirrhosis with CHB
- without history of antiviral therapy or discontinued antiviral therapy for more than 6 months
- for patients with compensated liver cirrhosis: HBV DNA≥4log copies/ml if HBeAg positive,HBV DNA≥3log copies/ml if HBeAg negative
- for patients with uncompensated liver cirrhosis:HBV DNA positive
Exclusion Criteria:
- coinfection with HCV,HDV and HIV
- AFP≥100mg/L or HCC diagnosed by iconography
- with severe cardiovascular, respiratory and endocrinology diseases or autoimmune diseases
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: telbivudine
|
telbivudine 600mg/d 96 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum HBV DNA
Time Frame: 48 weeks
|
serum HBV DNA negativity and decline from baseline at week 48
|
48 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum HBeAg
Time Frame: 48 weeks
|
rate of HBeAg seroconversion and HBeAg loss
|
48 weeks
|
Child-pugh score
Time Frame: 48 weeks
|
the average decline of Child-pugh score at week 48 from baseline
|
48 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Chuanwu Zhu, Doctor, The Fifth People's Hospital of Suzhou
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2011
Primary Completion (Anticipated)
December 1, 2012
Study Completion (Anticipated)
December 1, 2013
Study Registration Dates
First Submitted
June 23, 2011
First Submitted That Met QC Criteria
June 23, 2011
First Posted (Estimate)
June 27, 2011
Study Record Updates
Last Update Posted (Estimate)
June 27, 2011
Last Update Submitted That Met QC Criteria
June 23, 2011
Last Verified
June 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Enterovirus Infections
- Picornaviridae Infections
- Fibrosis
- Hepatitis B
- Hepatitis
- Hepatitis A
- Hepatitis B, Chronic
- Hepatitis, Chronic
- Liver Cirrhosis
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Telbivudine
Other Study ID Numbers
- szwy20110610
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Cirrhosis
-
Postgraduate Institute of Medical Education and...Society for the Study of Liver Diseases, Chandigarh ( India )UnknownDecompensated Cirrhosis of LiverIndia
-
The Second Affiliated Hospital of Chongqing Medical...RecruitingFibrosis, Liver | Cirrhosis, LiverChina
-
SUUMC Central Military Hospital Dr Carol DavilaRecruiting
-
The Cleveland ClinicRecruiting
-
The Cleveland ClinicRecruitingCirrhosis, LiverUnited States
-
University of PittsburghNational Institute on Drug Abuse (NIDA)CompletedCirrhosis, LiverUnited States
-
Beth Israel Deaconess Medical CenterAmerican Association for the Study of Liver Diseases FoundationCompleted
-
Asian Institute of Gastroenterology, IndiaCompletedCirrhosis, LiverIndia
-
Sherief Abd-ElsalamUnknown
Clinical Trials on telbivudine
-
Nanfang Hospital of Southern Medical UniversityNovartis; Major Science and Technology Special Project of China Eleventh Five-yearUnknown
-
Novartis PharmaceuticalsCompletedAn Extension to Viral Kinetics Study of Telbivudine and Entecavir in Adults With Chronic Hepatitis BChronic Hepatitis BKorea, Republic of
-
Chang Gung Memorial HospitalCompletedVirus Diseases | Disorder Related to Transplantation | Injury Due to Exposure to External Cause
-
Beijing Ditan HospitalUnknownImmune Globulin, Prophylaxis, Telbuvidine, Vaccine
-
Yonsei UniversityUnknownChronic Hepatitis BKorea, Republic of
-
Nanfang Hospital of Southern Medical UniversityNovartis; Major Science and Technology Special Project of China Eleventh Five-yearCompleted
-
Southeast University, ChinaCompletedChronic Hepatitis B | Pregnancy Complications | High Viral Load | Elevated Alanine Aminotransferase LevelsChina
-
Novartis PharmaceuticalsCompletedChronic Hepatitis BBelgium, Germany, United Kingdom, Philippines
-
NovartisNovartis PharmaceuticalsCompletedHepatitis BHong Kong, Singapore, New Zealand
-
Novartis PharmaceuticalsWithdrawnCompensated Chronic Hepatitis BUnited States, Puerto Rico